Product Name: Phase 1 Configuration – Modular Peptide Systems A+C+E Configuration Classification: Initial Framework Configuration Product Information:

• Configuration Type: Multi-Module Peptide Framework
• Included Modules: A, C, E
• Total Modules: 3
• System Compatibility: Modular Peptide System Framework
• Testing Methodology: HPLC-UV-MS
• Analytical Verification: ISO/IEC 17025 Accredited Laboratory
• Evaluation Format: Standalone Configuration or Sequential Configuration Framework

Analytical Composition: Module A

• Total Peptide Content: 0.10%
• Palmitoyl Tripeptide-1
• Palmitoyl Tetrapeptide-7

Module C

• Total Peptide Content: 0.52%
• Dipeptide-2
• Acetyl Tetrapeptide-5
• Palmitoyl Tetrapeptide-7
• Plus 0.30% Caffeine

Module E

• Total Peptide Content: 0.13%
• Acetyl Octapeptide-3 (SNAP-8)
• Tetrapeptide-21
• AHK-Cu

Cumulative Composition

• Seven distinct peptides
• Four structural peptide classes
• One non-peptide supporting component

Product Description: Phase 1 is one of three configurations within PHP’s Modular Peptide System, a modular framework of peptide formulations designed for research evaluation. Configurations represent defined combinations of individual modules (A through E) assembled to provide broader comparative frameworks than standalone module evaluation. Phase 1 combines three distinct modules within a single configuration: the foundational composition (Module A), the precision composition (Module C), and the composite multi-class composition (Module E). Together, these modules establish a broad-spectrum peptide environment spanning multiple peptide classes, concentration profiles, and formulation architectures. Each included module is independently verified through ISO/IEC 17025-accredited analytical testing using HPLC-UV-MS methodology. Batch-specific Certificates of Analysis are available through the COA-Topicals library. Research Framework:

• Foundational entry point into the Topical System
• Broadest peptide-class diversity among the three configurations
• Integrates foundational, localized, and composite compositions
• Six peptides across four structural classes
• Suitable for standalone configuration evaluation

Phase 1 may be evaluated independently as a continuous comparative framework or sequentially alongside Phase 2 within a structured evaluation protocol. When configurations are sequenced within a 24-hour evaluation cycle, defined separation intervals (typically ~12 hours) between configurations allow the analytical contributions of each to be observed without compositional overlap. Configuration Characteristics:

• Combines three distinct formulation architectures
• Includes both single-class and multi-class peptide compositions
• Incorporates the system’s highest peptide concentration module (Module C)
• Includes the system’s most analytically complex module (Module E)
• Establishes the broadest peptide-class diversity available within a single configuration
• Provides representation across multiple peptide concentration levels

Position Within The System: Within the Topical System framework, Phase 1 functions as the initial configuration and serves as the foundational entry point into the modular architecture. By combining Modules A, C, and E, Phase 1 introduces the principal formulation categories utilized throughout the system while maintaining broad peptide-class diversity and compositional complexity. Unlike Phase 2, which focuses on elevated-concentration and chemistry-class-specific compositions, Phase 1 emphasizes diversity across peptide structures, concentrations, and formulation approaches. Together, the three modules establish a comprehensive baseline framework for comparative evaluation. Configuration Specifications:

• Included Modules: A + C + E
• Total Peptides: 7
• Structural Classes: 4
• Supporting Components: Caffeine
• Highest Peptide Concentration Module: Module C (0.52%)
• Most Complex Module: Module E
• Verification: ISO/IEC 17025 HPLC-UV-MS
• Packaging: Opaque Airless UV-Protective Packaging

Analytical Verification: Each module within Phase 1 is independently verified through ISO/IEC 17025-accredited analytical testing utilizing HPLC-UV-MS methodology. Batch-specific Certificates of Analysis are available through the COA-Topicals library. All included formulations are housed in opaque, airless, light-protective packaging designed to support compositional integrity throughout storage and evaluation. Compliance Notice: Phase 1 Configuration is FOR RESEARCH USE ONLY — NOT FOR HUMAN OR VETERINARY USE. This product is not a drug, cosmetic, food, or dietary supplement and has not been evaluated or approved by the U.S. Food and Drug Administration. It is intended solely for lawful in vitro research and not for any human or animal use. By purchasing this product, buyer represents and warrants that it will be used exclusively for lawful in vitro research in compliance with all applicable laws and regulations, and assumes all responsibility for any use inconsistent with this notice.